StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & Company
May 7, 2018 6:20 AM
Needham & Company raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $109.00 (from $75.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Sarepta Therapeutics (SRPT) PT Raised to $96 at H.C. Wainwright
May 7, 2018 8:17 AM
Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital
May 4, 2018 8:50 AM
Sarepta Therapeutics (SRPT) PT Lowered to $90 at H.C. Wainwright
May 4, 2018 7:14 AM
Sarepta Therapeutics' (SRPT) In Line Quarter Shifts Focus To R&D Day
May 4, 2018 7:01 AM
Sarepta Therapeutics (SRPT) PT Raised to $91 at Morgan Stanley
May 4, 2018 6:44 AM
Sarepta Therapeutics (SRPT): R&D Day Should Reveal Gene Therapy Data - Baird
May 4, 2018 6:43 AM
Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to Perform
May 4, 2018 5:31 AM
Sarepta Therapeutics (SRPT) PT Lowered to $90 at JMP Securities
May 4, 2018 4:08 AM
Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to Perform
May 4, 2018 2:37 AM
Sarepta Therapeutics (SRPT) Tops Q1 EPS by 4c
May 3, 2018 4:05 PM
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies
May 3, 2018 4:01 PM
